Presidential Selection - Poster Guidelines

Upload the Final Abstract and Register by May 20 by logging in the Abstract Submission Portal with your original account and password.

1. **Confirm your Abstract Content** [in “Edit Draft/ Submitted Abstract Overview” Tab]
   No further edit or modification will be accepted after submission or after the due-date.

2. **Upload your ePoster Document** [in “Edit Draft/ Submitted Abstract Overview” Tab]
   ePoster Template: [Download HERE](#)
   - Slide Size: (W)28.575cm x (H) 36.777cm
   - Abstract Title: Times New Roman, Bold, 45pt, justify
   - Authors and Affiliations: Times New Roman, 20pt, center text
   - Abstract Content: Times New Roman, 24pt, justify
   - File size: Limited to 20MB
   - Content Required: Paper ID/ Authors’ names/ Authors’ Affiliations/ City
   - File Name: *Paper ID* _Presenter Name_ *Abstract Title* (Check Paper ID in your acceptance letter)
     *(e.g. P017(77)_Vera Huang_ Abstract Title.)*
   - *Please upload the ePoster by May 20, and the Conference will do the printing and set up for you.*

3. **Complete Registration** [in “Presenter Registration” Tab]
   Presenters are secured to have the Early Bird Rate. Please use the code and [register via the](#)
   Abstract Submission Portal.

Please make sure to complete above 3 steps by May 20. **Accepted abstracts that failed to complete any of above steps will be automatically withdrawn from the final program.**

**POSTER PRINTING**
Please provide your ePoster, and the Conference will do the printing and set up for you.

**POSTER DISPLAY AREA**
- Poster: 2F of Taipei International Convention Center (TICC)
- ePoster: 1F South Foyer
- Opening Hours: 08:00-17:00, June 23/ 08:00-15:30, June 24
REMOVING POSTER
15:30- 16:00, June 24 (SUN)
Posters must be removed by poster presenters at the end of the Conference. The Conference Organizers will not be responsible for any material left behind or for loss or damage. Posters left on site after the Conference will be recycled without further notice.

PRESIDENTIAL SELECTION – POSTER SHORTLITED CANDIDATES

<table>
<thead>
<tr>
<th>Paper ID</th>
<th>Category</th>
<th>Paper Title</th>
<th>Presenter</th>
<th>City</th>
</tr>
</thead>
<tbody>
<tr>
<td>O-012 (192)</td>
<td>4. HBV</td>
<td>Influence of AFP level during direct antiviral therapy on HBeAg loss</td>
<td>Rachel Wen-juei Jeng</td>
<td>Taipei</td>
</tr>
<tr>
<td>O-017 (194)</td>
<td>8. HCC</td>
<td>Hepatitis B core-related antigen is a predictive factor for non-B, non-C hepatocellular carcinoma</td>
<td>Yi-Chung Hsieh</td>
<td>Taoyuan</td>
</tr>
<tr>
<td>P-022 (69)</td>
<td>4. HBV</td>
<td>Chronic hepatitis B associates with an increased risk of B cell non-Hodgkin's lymphoma and multiple myeloma</td>
<td>Tung-hung Su</td>
<td>Taipei</td>
</tr>
<tr>
<td>P-038 (138)</td>
<td>4. HBV</td>
<td>Predicting risk of hepatocellular carcinoma for patients with chronic hepatitis B using serum levels of hepatitis B virus DNA splicing</td>
<td>Mei-hung Pan</td>
<td>Taipei</td>
</tr>
<tr>
<td>P-055 (37)</td>
<td>6. HCV</td>
<td>Daclatasvir plus asunaprevir for the treatment of HCV genotype 1b infection in Chinese patients with or without compensated cirrhosis: an integrated analysis</td>
<td>Lai Wei</td>
<td>Beijing</td>
</tr>
<tr>
<td>P-062 (48)</td>
<td>6. HCV</td>
<td>Elevated Serum Ferritin Level Associated with Hepatic Steatosis and Fibrosis in Hepatitis C Virus Infected Patients</td>
<td>Batbold Batsaikhan</td>
<td>Ulaanbaatar</td>
</tr>
<tr>
<td>P-115 (94)</td>
<td>8. HCC</td>
<td>The effect of primary prophylaxis therapy for large esophageal varices in patients with hepatocellular carcinoma</td>
<td>Hsiao Sheng Lu</td>
<td>Taipei</td>
</tr>
<tr>
<td>P-126 (157)</td>
<td>8. HCC</td>
<td>Comprehensive evaluation of the receptor tyrosine kinase family in human hepatocellular carcinogenesis</td>
<td>Tony Kuo</td>
<td>Linkou</td>
</tr>
<tr>
<td>P-137 (105)</td>
<td>9. Other</td>
<td>Effect of Ivabradine, a Funny Current (If) Inhibitor, on Portal Hypertensive Rats</td>
<td>Ching-Chih Chang</td>
<td>Taipei</td>
</tr>
</tbody>
</table>
### Table of Papers

<table>
<thead>
<tr>
<th>Paper ID</th>
<th>Category</th>
<th>Paper Title</th>
<th>Presenter</th>
<th>City</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-148 (129)</td>
<td>9. Other</td>
<td>Chronic hepatitis B exhibited higher rate of hepatocellular carcinoma occurrence than chronic hepatitis C in cirrhotic patients after effective antiviral therapies: The difference of common risk factors</td>
<td>Kuo-chin Chang</td>
<td>Kaohsiung</td>
</tr>
</tbody>
</table>

* Shortlisted Presidential Poster Award candidates requires no further presentation. The result will be announced onsite at the Closing Ceremony.

**AWARD PRESENTING**

The award with US$ 1,000 will be given to the best 3 papers presented, and Presidential Award candidates must attend the Award Presenting held at the Closing Ceremony:

- **Time:** 15:20-16:00, June 24, 2018
- **Venue:** Plenary Hall, TICC

---

**Conference Secretariat**

**Ms. Vera Huang**

Email: secretariat@apasl-hbv-2018.org
Tel: +886-2-8780-5688 ext. 173